Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim, a provider of plasmid DNA, and Germany-based Geneart have announced their technology and sales collaboration.
Subscribe to our email newsletter
The collaboration includes a transfer of Boehringer Ingelheim technology to Geneart for the production and purification of plasmid DNA. The two partner companies also plan to closely collaborate in the distribution and marketing of their complementary services.
The collaboration also offers a unique system solution for the development of DNA-based pharmaceuticals. Geneart will use the Boehringer Ingelheim production and purification technology to deliver DNA-based agents for research, development and preclinical studies. Boehringer Ingelheim will produce the pharmaceuticals under current good manufacturing practice conditions for the subsequent clinical phases and the market.
Customers in research and industry additionally benefit from Geneart’s expertise in software-assisted design of gene sequences and from the production of these improved sequences via gene synthesis.
Ralf Wagner, CEO of Geneart, said: “The collaboration with Boehringer Ingelheim opens new horizons to support customer projects in the fast growing market for DNA-based therapeutics and vaccines.”